Oramed Pharmaceuticals Inc.
(ORMP) – NasdaqCM
10.62
-0.20 (-1.85%)
Refresh Quote
Exchange :NASDAQ (US Dollar)
Ric Code :ORMP
Volume :32,250
Date :10-19-2017
* Minimum 20 minute delay See terms

Oramed Pharmaceuticals (NASDAQ: ORMP) has developed innovative technology to transform injectable treatments into oral therapies.

Oramed’s flagship product, an oral insulin capsule, can better the lives of millions of diabetics around the world – allowing, amongst other things, type 2 patients to begin insulin therapy earlier without fear of needles… [READ MORE >]

Oramed to Present at Oligonucleotide and Peptide Therapeutics (OPT) Boston Conference on March 28, 2017

三月 22nd, 2017|

JERUSALEM, March 22, 2017 /PRNewswire/ — Oramed Pharmaceuticals Inc. (NASDAQ: ORMP) (www.oramed.com), a clinical-stage pharmaceutical company focused on the development of oral drug delivery systems, announced today that Dr. Miriam Kidron, Oramed’s Chief Scientific Officer, […]

Oramed Appoints Dr. Ronald Law as Chief Strategy Officer

三月 21st, 2017|

JERUSALEM, March 21, 2017 /PRNewswire/ — Oramed Pharmaceuticals Inc. (NASDAQ: ORMP) (www.oramed.com), a developer of oral drug delivery systems, announced today the appointment of Dr. Ronald Law to the newly created position of Chief Strategy Officer.

“We […]

Oramed to Present at BIO CEO and Investor and Disruptive Growth and Healthcare Conferences

二月 7th, 2017|

JERUSALEM, Feb. 7, 2017  /PRNewswire/ — Oramed Pharmaceuticals Inc. (NASDAQ: ORMP) (www.oramed.com), a clinical-stage pharmaceutical company focused on the development of oral drug delivery systems, announced today that the Company will participate in the upcoming […]

Oramed’s ORMD-0901 (Oral GLP-1 Analog) Found Safe and Well Tolerated in Phase Ib Study

十一月 29th, 2016|

Preparing to submit IND and commence U.S. FDA Phase IIb trial in 2017

JERUSALEM, Nov. 29, 2016  /PRNewswire/ — Oramed Pharmaceuticals Inc. (NASDAQ: ORMP) (www.oramed.com), a developer of oral drug delivery systems, today announced it successfully […]